Canada markets close in 2 hours 3 minutes
  • S&P/TSX

    19,097.76
    -10.01 (-0.05%)
     
  • S&P 500

    4,098.39
    +35.35 (+0.87%)
     
  • DOW

    33,923.07
    +335.41 (+1.00%)
     
  • CAD/USD

    0.8204
    -0.0041 (-0.49%)
     
  • CRUDE OIL

    63.49
    -2.59 (-3.92%)
     
  • BTC-CAD

    58,849.26
    -8,591.25 (-12.74%)
     
  • CMC Crypto 200

    1,308.87
    -79.03 (-5.69%)
     
  • GOLD FUTURES

    1,823.10
    +0.30 (+0.02%)
     
  • RUSSELL 2000

    2,137.90
    +2.76 (+0.13%)
     
  • 10-Yr Bond

    1.6660
    -0.0290 (-1.71%)
     
  • NASDAQ

    13,050.95
    +19.27 (+0.15%)
     
  • VOLATILITY

    24.89
    -2.70 (-9.79%)
     
  • FTSE

    6,963.33
    -41.30 (-0.59%)
     
  • NIKKEI 225

    27,448.01
    -699.50 (-2.49%)
     
  • CAD/EUR

    0.6796
    -0.0028 (-0.41%)
     

KDMN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Kadmon Holdings, Inc.

  • Oops!
    Something went wrong.
    Please try again later.
Newsfile Corp.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - April 13, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Kadmon Holdings, Inc. ("Kadmon Holdings") (NASDAQ: KDMN) between October 1, 2020 and March 10, 2021.

If you suffered a loss, contact us at the link below. There is no cost or obligation to you.
http://www.wongesq.com/pslra-1/kadmon-holdings-inc-loss-submission-form?prid=14673&wire=5

Allegations against KDMN include that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the Belumosudil NDA was incomplete and/or deficient; (ii) the additional new data that the Company submitted in support of the Belumosudil NDA in response to an information request from the FDA materially altered the NDA submission; (iii) accordingly, the initial Belumosudil NDA submission lacked the degree of support that the Company had led investors to believe; (iv) accordingly, the FDA was likely to extend the PDUFA target action date to review the Belumosudil NDA; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

If you suffered a loss in Kadmon Holdings you have until June 2, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/80363